GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » Accounts Payable

Galderma Group AG (XSWX:GALD) Accounts Payable : CHF586 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Accounts Payable?

Galderma Group AG's Accounts Payable for the quarter that ended in Jun. 2024 was CHF586 Mil.

Galderma Group AG's quarterly Accounts Payable stayed the same from . 20 (CHF0 Mil) to Jun. 2023 (CHF0 Mil) but then increased from Jun. 2023 (CHF0 Mil) to Jun. 2024 (CHF586 Mil).

Galderma Group AG Accounts Payable Historical Data

The historical data trend for Galderma Group AG's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Accounts Payable Chart

Galderma Group AG Annual Data
Trend
Accounts Payable

Galderma Group AG Semi-Annual Data
Jun23 Jun24
Accounts Payable - 586.33

Galderma Group AG Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Galderma Group AG Accounts Payable Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » Accounts Payable
Comparable Companies
Traded in Other Exchanges
GALDY:USA GDERF:USA GALDz:UK
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines